Issue 1,693: May 17, 2023
 
Top Stories
 
Immunize.org Pages and Handouts
 
Featured Resources
 
Notable Publications
 
Global News
 
Upcoming Events
 
Top Stories

CDC releases new interim VISs for hepatitis B and pneumococcal conjugate vaccines

Immunize.org posted two new interim VISs, published by CDC. The hepatitis B vaccine VIS reflects the 2022 ACIP recommendation for catch-up hepatitis B vaccination of all people younger than age 60 years and the option to catch up those age 60 and older. The pneumococcal conjugate VIS incorporates newer pneumococcal conjugate vaccines (PCV15 and PCV20).

Immunize.org has updated its reference documents related to the use of VISs, You Must Provide Patients with Vaccine Information Statements (VISs) – It's Federal Law! and Dates of Current Vaccine Information Statements (VISs), with the publication dates of these new VISs.

    

Related Links


The COVID-19 Public Health Emergency ended May 11. For now, there are few changes for vaccination providers.

On May 11, 2023, the U.S. Department of Health and Human Services (HHS) ended the federal Public Health Emergency (PHE) for COVID-19, declared under Section 319 of the Public Health Service (PHS) Act. During the course of this emergency, 270 million Americans received nearly 700 million doses of COVID-19 vaccines.

At the end of the COVID-19 PHE on May 11, Americans will continue to be able to access COVID-19 vaccines at no cost, just as they have during the COVID-19 PHE, due to the requirements of the CDC COVID-19 Vaccination Program Provider Agreement. People will also continue to be able to access COVID-19 treatments just as they have during the COVID-19 PHE.

HHS has announced its plan to create the Bridge Access Program for COVID-19 Vaccines and Treatments Program in coming months to ensure access to COVID-19 vaccines for uninsured Americans once federally purchased vaccines and treatment are no longer available. The program is intended to help maintain access to COVID-19 care for uninsured people at their local pharmacies, through existing public health sites, and at their local health centers.

The end of the PHE does not alter the FDA’s emergency use authorizations (EUAs) for COVID-19 products, including vaccines. In addition, certain liability protections extended to vaccination providers under the Public Readiness and Emergency Preparedness (PREP) Act have been extended. Those who regularly use surveillance data on COVID-19 from CDC will see significant changes to the data reported because certain types of data were only available under the PHE. CDC will also update available data less frequently.

Additional details and links to resource documents, including more information about COVID-19 testing and treatments, appear in the HHS Fact Sheet on the end of the COVID-19 PHE.

Related Links
Immunize.org updates its “Vaccines: COVID-19” main page to reflect recent CDC and FDA changes, expiry of remaining Janssen product

Immunize.org updated its Vaccines: COVID-19 main page. The updates reflect the removal of authorization for monovalent mRNA vaccines and removes references to the Janssen COVID-19 Vaccine (Johnson & Johnson), which is no longer available in the United States. The page contains updated links to the FDA Emergency Use Authorization (EUA) Fact Sheets for bivalent mRNA vaccines. The web page continues to direct visitors seeking quick links to all print-ready federal fact sheets and COVID-19 vaccination resources to Immunize.org’s Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools, which is updated at least monthly. The web page also continues to link to other important government and partner websites.

Bookmark Immunize.org's Vaccines: COVID-19 main page to connect with a comprehensive list of resources from CDC and FDA including fact sheets, clinical considerations, vaccine administration tools, and storage and handling guidance.



Related Links


Spotlight: Immunize.org’s “Standing Orders Templates for Administering Vaccines” main page helps you simplify your vaccination practice

Immunize.org’s Standing Orders Templates for Administering Vaccines main page includes 46 straightforward standing order templates that allow qualified healthcare professionals to assess the need for and administer vaccines to patients meeting certain criteria, such as age or underlying medical condition. In addition to templates developed by Immunize.org, the page includes links to CDC’s standing orders templates for all COVID-19 vaccines and all age groups, as well as CDC's standing orders template for mpox vaccination with Jynneos (Bavarian Nordic).

Standing orders help you increase vaccination rates by enabling assessment and vaccination of the patient without the need for clinician examination or a direct order from the attending provider at the time of the interaction. Standing orders can be established for the administration of one or more specific vaccines to a broad or narrow set of patients in healthcare settings such as clinics, hospitals, pharmacies, and long-term care facilities.



Visit the Standing Orders Templates for Administering Vaccines main page on Immunize.org to view the standing orders templates.


Vaccines in the news

These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.


Immunize.org Pages and Handouts

Immunize.org updates "You Must Provide Patients with Vaccine Information Statements (VISs) – It's Federal Law!" and "Dates of Current Vaccine Information Statements (VISs)"

As noted in our top stories, Immunize.org updated two provider resources with the publication date of the revised Hepatitis B Vaccine and Pneumococcal Conjugate (PCV) VISs.

    

Related Links
Correction: Immunize.org’s Chinese translation of “After the Shots…What to Do If Your Child Has Discomfort” dated 3/29/2023 removed to correct error. Use new version.

Immunize.org was notified on May 10 to the presence of an error in the 3/29/2023 version of the Chinese translation of Immunize.org’s popular handout, After the Shots…What to Do If Your Child Has Discomfort. The version was immediately taken down from our website for correction by the translation service used by Immunize.org. Those who downloaded the Chinese version should discard it and replace it with the May 2023 version. The corrected translation will be posted on Immunize.org's Handouts: Chinese Translations main page and will be announced in IZ Express. Immunize.org is grateful to the alert reader who notified us of the mistranslation.


Featured Resources

Organizing a new vaccination program? Use Immunize.org’s Vaccinating Adults: A Step-by-Step Guide—free to download by chapter or in its entirety.

Download Immunize.org’s free 142-page book on adult vaccination to help build your program and train your team: Vaccinating Adults: A Step-by-Step Guide (Guide).



This thorough "how to" guide on adult vaccination provides easy-to-use, practical information covering all essential activities. It helps vaccine providers enhance their existing adult vaccination services or introduce them into any clinical setting.

The Guide is available to download/print either by chapter or in its entirety free at www.immunize.org/guide. The National Vaccine Program Office and CDC both supported the development of the Guide and provided early technical review.

The Guide is a valuable resource to assist providers in increasing adult vaccination rates. Be sure to get a copy today!

Please note: this guide was produced in 2017, before the COVID-19 era, and reflects the recommendations of that time.

Related Links


While supplies last! Laminated versions of CDC’s 2023 immunization schedules still available.

Immunize.org's laminated versions of the 2023 U.S. child and adolescent immunization schedule and the 2023 U.S. adult immunization schedule are still available. Order while supplies last. Once sold out, we will not print more until 2024.

While the schedules are available online from CDC at no cost, Immunize.org’s laminated schedules are ideal for use in any busy healthcare setting. Their tough coating can be wiped down, and they’re durable enough to stand up to a year of use.

  • Length: Each schedule with appendices is 12 pages
  • Size: Standard 8.5” X 11” booklet format
  • Full Color: With color coding for easy reading, our laminated schedules replicate the original CDC formatting, including the essential tables and notes
  • Bonus: The adult schedule includes Immunize.org’s popular 1-page handout summarizing the dose, route, and needle length recommendations for all vaccines and recipients

    

Pricing for Each Schedule
$10.00: 1 copy
$  9.50 each: 2–4 copies
$  8.50 each: 5–19 copies
$  7.50 each: 20–99 copies
$  6.00 each: 100–499 copies
$  5.00 each: 500–999 copies
$  4.00 each: 1,000–1,999 copies
$  3.25 each: 2,000+ copies

Visit Shop Immunize.org: Laminated Schedules to view images of each page and order today!

For additional information, call 651-647-9009 or email admininfo@immunize.org.

Related Links


Notable Publications

"Progress toward Poliomyelitis Eradication—Worldwide, January 2021–March 2023" published in MMWR

CDC published Progress toward Poliomyelitis Eradication—Worldwide, January 2021–March 2023 on May 12 in MMWR. A portion of the summary appears below.

Endemic transmission of wild poliovirus type 1 (WPV1) continues only in Afghanistan and Pakistan. . . .

In 2022, Malawi and Mozambique reported WPV1 cases linked to a Pakistan strain, the first WPV1 cases in the African region since 2016. During 2022 and 2023, Afghanistan and Pakistan reported WPV1 cases. Circulating vaccine-derived polioviruses were detected in areas of the world where poliovirus had been eliminated. Cocirculation of more than one poliovirus type occurred in multiple countries. . . .

The detections of poliovirus in areas where it had been previously eliminated underscore the threat of continued poliovirus spread to any area where the population is insufficiently vaccinated against poliovirus.

Access the MMWR article in HTML or PDF.

Related Link

  • MMWR's main page provides access to MMWR Weekly and its companion publications

Global News

IVAC updates its VIEW-hub, an interactive platform to visualize vaccine use around the world

The Johns Hopkins University International Vaccine Access Center (IVAC) updated its VIEW-hub, a map-based platform for visualizing data on vaccine use, impact, and coverage status globally and in the 73 countries receiving vaccines from Gavi. In addition to data on human papillomavirus, typhoid conjugate, pneumococcal conjugate, rotavirus, Haemophilus, and inactivated polio vaccines, VIEW-hub now includes COVID-19 Vaccines Briefs, including effectiveness in children.



Explore the interactive maps here.

Related Link


Upcoming Events

On-Demand: American College Health Association completes posting of its five-part webinar series, Facts or Fakes? Promoting Health Literacy Skills with Your Students; CE available

The American College Health Association (ACHA) offered a free, five-part webinar series, Facts or Fakes? Promoting Health Literacy Skills with Your Students. This five-part webinar series provides tools to help students and others navigate misinformation, disinformation, and the infodemic. Webinars include:

Up to 5 hours of credit are available for CNE, CME, and CHES, and 1 CE is available for counselors for session 2.

Register for the free webinars.


For more upcoming events, visit our Calendar of Events.

About IZ Express

IZ Express is supported in part by Grant No. 1NH23IP922654 from CDC’s National Center for Immunization and Respiratory Diseases. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.

IZ Express Disclaimer
ISSN 2771-8085

Editorial Information

  • Editor-in-Chief
    Kelly L. Moore, MD, MPH
  • Managing Editor
    John D. Grabenstein, RPh, PhD
  • Associate Editor
    Sharon G. Humiston, MD, MPH
  • Writer/Publication Coordinator
    Taryn Chapman, MS
    Courtnay Londo, MA
  • Style and Copy Editor
    Marian Deegan, JD
  • Web Edition Managers
    Arkady Shakhnovich
    Jermaine Royes
  • Contributing Writer
    Laurel H. Wood, MPA
  • Technical Reviewer
    Kayla Ohlde

This page was updated on .